Recent News

• 12.08.2025 - ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
• 11.19.2025 - Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
• 11.07.2025 - Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.03.2025 - Cellectis to Present a Development Update for eti-cel at ASH 2025
• 10.31.2025 - Cellectis to Report Third Quarter Financial Results on November 7, 2025
• 10.16.2025 - Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
• 10.16.2025 - Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers

Recent Filings

• 12.05.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.19.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.19.2025 - EX-99.1 EX-99.1
• 11.07.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.07.2025 - EX-99.1 EX-99.1
• 11.03.2025 - EX-99.1 EX-99.1
• 11.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.31.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.31.2025 - EX-99.1 EX-99.1
• 10.17.2025 - EX-99.1 EX-99.1